Rebecca Araujo

DocwireNews

A pooled analysis of 10 clinical trials found that ibrutinib dose reductions were associated with lower rates of recurrent cardiac adverse events (AEs) in patients with B-cell malignancies. This study was presented as a poster at the <a href="https://www.hoparx.org/hopa-learn/conferences-events/" target="_blank" rel="noopener">Hematology/Oncology Pharmacy Association Annual Conference 2024</a>.&ldquo;Dose reduction is a potential AE management approach to optimize ibrutinib treatment outcomes and avoid early discontinuation,&rdquo; the authors wrote in their poster.Ten clinical trials were included, with patients treated for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or Waldenstr&ouml;m macroglobulinemia (WM). The daily starting dose was ibrutinib 420 mg for patients with CLL/SLL and WM and 560 mg for patients with MCL and MZL.The total pooled population was 1263 patients, of whom 234 experienced a cardiac AE. After exclusion of patients who had a dose reduction prior to cardiac AE or fatal cardiac AE with no prior cardiac AE, 222 patients remained in the analysis. Of this group, 22 patients had an ibrutinib dose reduction and 200 did not.The recurrence rate of cardiac AEs was lower in the subgroup of patients with a dose reduction. Fourteen percent of patients in the dose-reduction group experienced a grade 1-4 cardiac AE recurrence compared with 19% of the group without a dose reduction. Regarding serious AEs, 5% of the dose-reduction group had a recurrent serious AE compared with 11% of the no-reduction group. No patients in either group died due to recurrence of cardiac AEs.Dose reductions for cardiac AEs did not impact progression-free survival (PFS) in patients with a starting dose of 420 mg. The median PFS in the dose-reduction group was not reached at the time of data cutoff; in the no-reduction group, the median PFS was 34.8 months. The 24-month PFS rates were 94% and 71% in the dose-reduction and no-reduction groups, respectively. Across the entire cohort, the 24-month PFS rates were 91% and 63% in those who did or did not have a dose reduction, respectively.Similarly, overall survival (OS) was not negatively impacted by dose reductions in those with a starting dose of 420 mg. The 24-month OS in this subgroup was 94% and 83% in those with or without a dose reduction, respectively. The median OS was not reached in either group at data cut-off.&ldquo;Rates of recurrence of same/worse severity or serious cardiac AE were lower among patients who had an ibrutinib dose reduction than in patients without any dose reduction,&rdquo; the authors summarized. &ldquo;Oncology pharmacists provide dose reduction recommendations for cardiac AEs, which may enable patients to continue to benefit from long-term ibrutinib and mitigate the risk of AE recurrence or worsening.&rdquo;<h4>Reference</h4>Stephens D, Brown JR, Ma S, et al. Ibrutinib dose modifications for management of cardiac adverse events in patients with b-cell malignancies: pooled analysis of 10 clinical trials. Poster. Presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024; April 3-6, 2024; Tampa, Florida.

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Study Investigates Recurrent Cardiac Events, Outcomes After Ibrutinib Dose Reduction

HOPA Annual Conference 2024

Ibrutinib dose reductions were associated with lower rates of recurrent cardiac adverse events in patients with B-cell malignancies.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe